Cargando…

Biophysical studies of amorphous protein aggregation and in vivo immunogenicity

Amorphous protein aggregates are oligomers that lack specific, high-order structures. Soluble amorphous aggregates are smaller than ~1 µm. Despite their lack of high-order structure, amorphous protein aggregates exhibit specific biophysical properties such as reversibility of formation, density, con...

Descripción completa

Detalles Bibliográficos
Autor principal: Kuroda, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684872/
https://www.ncbi.nlm.nih.gov/pubmed/36465085
http://dx.doi.org/10.1007/s12551-022-01011-y
_version_ 1784835383571251200
author Kuroda, Yutaka
author_facet Kuroda, Yutaka
author_sort Kuroda, Yutaka
collection PubMed
description Amorphous protein aggregates are oligomers that lack specific, high-order structures. Soluble amorphous aggregates are smaller than ~1 µm. Despite their lack of high-order structure, amorphous protein aggregates exhibit specific biophysical properties such as reversibility of formation, density, conformation, and biochemical stability. Our mutational analysis using a Solubility Controlling Peptide (SCP) tag strongly suggests that amorphous aggregation of small globular proteins can significantly increase in vivo immune response and that the magnitude of enhanced immune responses depends on the aggregates’ biophysical and biochemical properties. We propose that SCP tags might help develop subunit (protein) adjuvant-free (immunostimulant-free) vaccines by controlling the aggregation propensity of target proteins.
format Online
Article
Text
id pubmed-9684872
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96848722022-11-28 Biophysical studies of amorphous protein aggregation and in vivo immunogenicity Kuroda, Yutaka Biophys Rev Review Amorphous protein aggregates are oligomers that lack specific, high-order structures. Soluble amorphous aggregates are smaller than ~1 µm. Despite their lack of high-order structure, amorphous protein aggregates exhibit specific biophysical properties such as reversibility of formation, density, conformation, and biochemical stability. Our mutational analysis using a Solubility Controlling Peptide (SCP) tag strongly suggests that amorphous aggregation of small globular proteins can significantly increase in vivo immune response and that the magnitude of enhanced immune responses depends on the aggregates’ biophysical and biochemical properties. We propose that SCP tags might help develop subunit (protein) adjuvant-free (immunostimulant-free) vaccines by controlling the aggregation propensity of target proteins. Springer Berlin Heidelberg 2022-11-23 /pmc/articles/PMC9684872/ /pubmed/36465085 http://dx.doi.org/10.1007/s12551-022-01011-y Text en © International Union for Pure and Applied Biophysics (IUPAB) and Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
spellingShingle Review
Kuroda, Yutaka
Biophysical studies of amorphous protein aggregation and in vivo immunogenicity
title Biophysical studies of amorphous protein aggregation and in vivo immunogenicity
title_full Biophysical studies of amorphous protein aggregation and in vivo immunogenicity
title_fullStr Biophysical studies of amorphous protein aggregation and in vivo immunogenicity
title_full_unstemmed Biophysical studies of amorphous protein aggregation and in vivo immunogenicity
title_short Biophysical studies of amorphous protein aggregation and in vivo immunogenicity
title_sort biophysical studies of amorphous protein aggregation and in vivo immunogenicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684872/
https://www.ncbi.nlm.nih.gov/pubmed/36465085
http://dx.doi.org/10.1007/s12551-022-01011-y
work_keys_str_mv AT kurodayutaka biophysicalstudiesofamorphousproteinaggregationandinvivoimmunogenicity